Next Article in Journal
Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements
Previous Article in Journal
Prospective Monitoring of Circulating Epithelial Tumor Cells (CETC) Reveals Changes in Gene Expression during Adjuvant Radiotherapy of Breast Cancer Patients
Article

Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients

1
Medical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Università Politecnica delle Marche, 60126 Ancona, Italy
2
Department of Pathological Anatomy and Histopathology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, 60126 Ancona, Italy
3
Medical Oncology Unit, Ospedale A. Murri, 63900 Fermo, Italy
4
Medical Oncology Unit, Ospedale Madonna del Soccorso, 63074 San Benedetto del Tronto, Italy
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(5), 3525-3536; https://doi.org/10.3390/curroncol28050303
Received: 7 August 2021 / Revised: 2 September 2021 / Accepted: 4 September 2021 / Published: 9 September 2021
Caveolin-1 (Cav-1) plays a key role in various neoplastic diseases and is upregulated in different cancers, including pancreatic ductal adenocarcinoma (PDAC). Furthermore, Cav-1 is critical for the uptake of albumin as well as nab-paclitaxel in PDAC cells. Here, we investigated the prognostic impact of Cav-1 expression in a cohort of 39 metastatic PDAC patients treated with different first-line chemotherapy regimens. We also assessed the predictive value of Cav-1 in patients treated with gemcitabine and nab-paclitaxel. Cav-1 expression was evaluated by immunohistochemistry staining in neoplastic and stromal cells, using metastatic sites or primary tumor tissue specimens. Higher levels of Cav-1 expression were associated with significantly worse overall survival (OS) and progression-free survival (PFS). No differences in OS were found between patients treated with gemcitabine + nab-paclitaxel vs. other chemotherapy options. Multivariate analysis for OS and PFS confirmed the independent prognostic role of Cav-1 expression. Our study evidenced a negative prognostic role of Cav-1 in patients affected by metastatic/locally advanced unresectable PDAC. Moreover, Cav-1 expression seems not to predict different response rates to different types of first-line treatment. Future prospective trials will be necessary to confirm the prognostic role of Cav-1 and explore Cav-1 specific inhibitors as a therapeutic option for advanced PDAC patients. View Full-Text
Keywords: Caveolin-1; pancreatic cancer; 1st line chemotherapy; prognosis Caveolin-1; pancreatic cancer; 1st line chemotherapy; prognosis
Show Figures

Figure 1

MDPI and ACS Style

Bittoni, A.; Giampieri, R.; Pecci, F.; Pinterpe, G.; Mandolesi, A.; Del Prete, M.; Zizzi, A.; Crocetti, S.; Liguori, C.; Mentrasti, G.; Cantini, L.; Pellei, C.; Bisonni, R.; Scarpelli, M.; Berardi, R. Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients. Curr. Oncol. 2021, 28, 3525-3536. https://doi.org/10.3390/curroncol28050303

AMA Style

Bittoni A, Giampieri R, Pecci F, Pinterpe G, Mandolesi A, Del Prete M, Zizzi A, Crocetti S, Liguori C, Mentrasti G, Cantini L, Pellei C, Bisonni R, Scarpelli M, Berardi R. Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients. Current Oncology. 2021; 28(5):3525-3536. https://doi.org/10.3390/curroncol28050303

Chicago/Turabian Style

Bittoni, Alessandro, Riccardo Giampieri, Federica Pecci, Giada Pinterpe, Alessandra Mandolesi, Michela Del Prete, Antonio Zizzi, Sonia Crocetti, Carolina Liguori, Giulia Mentrasti, Luca Cantini, Chiara Pellei, Renato Bisonni, Marina Scarpelli, and Rossana Berardi. 2021. "Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients" Current Oncology 28, no. 5: 3525-3536. https://doi.org/10.3390/curroncol28050303

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop